Download PDF

1. Company Snapshot

1.a. Company Description

HBM Healthcare Investments AG specializes in fund of funds and direct investments in middle market and mature companies.The fund prefers to invest in start up, early stage, mid stage, mid venture, late venture, and late stage private companies, unlisted emerging companies, small cap public companies, buyouts, growth capital, and private investment in public equities (PIPES).Within fund of funds, it invests in venture capital funds.


It also seeks to finance spin-offs of product lines or departments from larger corporations and the expansion or restructuring of established companies, seed stages, venture capital, expansion capital stages, spin-offs, and buyouts.The fund prefers to invest in the private and public companies in the healthcare sector with a focus on human medicine, drugs, pharma , biopharma, biotechnology, diagnostics, medical technology, and related industries.It seeks to make initial investments in companies whose primary products are in clinical development or the immediately preceding stage.


The fund typically invests globally with a focus on Asia Pacific, Asia, North America, and Europe.In case of public companies, it focuses on those which originate from its private portfolio.The fund increases its investment in portfolio companies by participating in a follow-on financing or after the portfolio company's IPO.


It may acquire majority participations in portfolio companies, usually takes a seat on the portfolio company's Board of Directors, and largely makes equity investments but may also invest through other instruments including convertible bonds, debt securities, structured products, and derivatives.The fund exits its portfolio companies through trade sale or IPO.

Show Full description

1.b. Last Insights on HBMN

Have nothing to say about that one ...

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Vicore Announces The Nomination Committee For The 2026 Annual General Meeting

Nov -03

Source:

Card image cap

Electra Therapeutics secures $183m to fund Phase II/III trial of ELA026

Oct -23

Source:

Card image cap

EQT Life Sciences Co-Leads USD 183 Million Series C Financing in Electra Therapeutics

Oct -22

Source:

Card image cap

Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer

Oct -22

Source:

Card image cap

Neuron23 Announces $96.5 Million Series D Financing and First Patient Dosed in Global Phase 2 NEULARK Clinical Trial of NEU-411 for Early Parkinson’s Disease

Jun -24

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.10%)

6. Segments

Investment and Related Activities

Expected Growth: 8.1%

Growing demand for healthcare services, increasing investment in biotechnology and pharmaceutical R&D, and advancements in medical technology are driving growth in the healthcare industry, presenting opportunities for HBM Healthcare Investments AG's investment segment.

7. Detailed Products

Pharmaceuticals

HBM Healthcare Investments AG invests in pharmaceutical companies that develop and commercialize innovative medicines for various therapeutic areas.

Biotechnology

The company invests in biotech companies that focus on research and development of novel biological products and technologies.

Medical Devices

HBM Healthcare Investments AG invests in companies that design and manufacture innovative medical devices for various medical specialties.

Digital Health

The company invests in digital health companies that develop software solutions for healthcare providers, payers, and patients.

Healthcare Services

HBM Healthcare Investments AG invests in healthcare service providers that offer outpatient and inpatient care, as well as healthcare management services.

8. HBM Healthcare Investments AG's Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for HBM Healthcare Investments AG is moderate, as there are alternative investment options available in the healthcare sector.

Bargaining Power Of Customers

The bargaining power of customers for HBM Healthcare Investments AG is low, as the company's investment portfolio is diversified and not heavily reliant on a single customer.

Bargaining Power Of Suppliers

The bargaining power of suppliers for HBM Healthcare Investments AG is moderate, as the company relies on a diverse range of suppliers for its investment activities.

Threat Of New Entrants

The threat of new entrants for HBM Healthcare Investments AG is high, as the healthcare investment sector is attractive and has low barriers to entry.

Intensity Of Rivalry

The intensity of rivalry for HBM Healthcare Investments AG is high, as the healthcare investment sector is highly competitive and fragmented.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 5.51%
Debt Cost 3.95%
Equity Weight 94.49%
Equity Cost 7.97%
WACC 7.75%
Leverage 5.83%

11. Quality Control: HBM Healthcare Investments AG passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
HBM Healthcare Investments

A-Score: 6.4/10

Value: 9.6

Growth: 3.8

Quality: 7.5

Yield: 5.6

Momentum: 4.0

Volatility: 7.7

1-Year Total Return ->

View Full Report
Stock-Card
MLP

A-Score: 5.7/10

Value: 4.8

Growth: 5.1

Quality: 3.1

Yield: 7.5

Momentum: 7.0

Volatility: 6.7

1-Year Total Return ->

View Full Report
Stock-Card
Altamir

A-Score: 4.9/10

Value: 3.8

Growth: 2.7

Quality: 5.8

Yield: 6.2

Momentum: 4.0

Volatility: 7.0

1-Year Total Return ->

View Full Report
Stock-Card
Tamburi Investment Partners

A-Score: 4.2/10

Value: 4.2

Growth: 2.8

Quality: 4.1

Yield: 2.5

Momentum: 3.0

Volatility: 8.7

1-Year Total Return ->

View Full Report
Stock-Card
Mattioli Woods

A-Score: 4.1/10

Value: 3.0

Growth: 3.8

Quality: 7.0

Yield: 3.8

Momentum: 4.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Bellevue

A-Score: 4.0/10

Value: 4.4

Growth: 2.4

Quality: 6.1

Yield: 9.4

Momentum: 0.0

Volatility: 1.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

206.0$

Current Price

206$

Potential

-0.00%

Expected Cash-Flows